Neurizon Therapeutics Limited has successfully developed an oral liquid formulation of NUZ-001, enhancing accessibility, ease of administration, and overall treatment experience for ALS patients. This patient-centric innovation strategy aims to support patients with all stages of ALS, especially those with swallowing difficulties. Our commitment to patient feedback led to this formulation, providing improved swallowing, flexible dosing, enteral administration, and simplified caregiver support. This advancement initiates a life cycle management strategy for NUZ-001, transforming it into a scalable treatment platform to maximize patient impact and commercial success.

The liquid formulation is currently being integrated into Neurizon’s ongoing clinical development program for NUZ-001 and will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. This human bioequivalence study is scheduled to commence in H1 CY 2026. For more details and inquiries, please reach out to us through the provided contacts. We value your input and look forward to driving innovation and creating new horizons for neurodegenerative diseases. Let's work together to make a difference.